Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors.

IF 2.8 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2025-03-01 Epub Date: 2024-08-17 DOI:10.1007/s12094-024-03596-0

Yang Yao, Minyue Zhang, Di Liu, Xiaoni Liu, Quanwei Li, Xiaojun Wang

{"title":"Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors.","authors":"Yang Yao, Minyue Zhang, Di Liu, Xiaoni Liu, Quanwei Li, Xiaojun Wang","doi":"10.1007/s12094-024-03596-0","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to evaluate the prognostic significance of changes in inflammatory markers in patients with Hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) treated with first-line lenvatinib plus a programmed cell death protein 1 (PD-1) inhibitor.Methods: This study retrospectively included 117 HBV-HCC patients treated with first-line lenvatinib in combination with a PD-1 inhibitor. Independent factors affecting progression-free survival (PFS) and overall survival (OS) were explored based on baseline indicators and inflammatory markers changes after one treatment cycle.Results: Multivariate analysis revealed that an alpha-fetoprotein (AFP) level <math><mo>⩾</mo></math> 400 ng/mL [hazard ratio (HR), 1.69; 95% confidence interval (CI), 1.11-2.58; P = 0.01] was identified as an independent risk factor, platelet-to-neutrophil ratio (PNR) <math><mo>⩽</mo></math> 65.43 (HR 0.50; 95% CI 0.30-0.84; P <math><mrow><mo><</mo> <mn>0.01</mn> <mo>)</mo></mrow> </math> and SII <math><mo>⩽</mo></math> 539.47 (HR 0.54; 95% CI 0.30-0.96; P = 0.03) were identified as independent protective factors for PFS. Additionally, multivariate analysis demonstrated that AFP <math><mo>⩾</mo></math> 400 ng/mL, HBV-HCC patients with diabetes mellitus (DM), and SII <math><mrow><mo>></mo> <mn>303.66</mn></mrow> </math> were independent risk factors of OS. The patients whose SII had increased after one cycle of treatment showed a poorer PFS (HR 1.61; 95 %CI 1.10-2.37; P = 0.015) and OS (HR 1.76; 95 % CI 1.15-2.70; P = 0.009) than patients whose SII had decreased. The objective response rate (ORR) was higher in the SII-decreased patients (47.5% vs 32.5%, P = 0.11). Mann-Whitney test found a significant difference in therapeutic response between the SII-increased patients and the SII-decreased patients (P = 0.04).Conclusion: SII can be associated with outcomes in patients with HBV-HCC treated with first-line lenvatinib plus PD-1 inhibitors.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1155-1165"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-024-03596-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to evaluate the prognostic significance of changes in inflammatory markers in patients with Hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) treated with first-line lenvatinib plus a programmed cell death protein 1 (PD-1) inhibitor.

Methods: This study retrospectively included 117 HBV-HCC patients treated with first-line lenvatinib in combination with a PD-1 inhibitor. Independent factors affecting progression-free survival (PFS) and overall survival (OS) were explored based on baseline indicators and inflammatory markers changes after one treatment cycle.

Results: Multivariate analysis revealed that an alpha-fetoprotein (AFP) level $⩾$ 400 ng/mL [hazard ratio (HR), 1.69; 95% confidence interval (CI), 1.11-2.58; P = 0.01] was identified as an independent risk factor, platelet-to-neutrophil ratio (PNR) $⩽$ 65.43 (HR 0.50; 95% CI 0.30-0.84; P $< 0.01)$ and SII $⩽$ 539.47 (HR 0.54; 95% CI 0.30-0.96; P = 0.03) were identified as independent protective factors for PFS. Additionally, multivariate analysis demonstrated that AFP $⩾$ 400 ng/mL, HBV-HCC patients with diabetes mellitus (DM), and SII $> 303.66$ were independent risk factors of OS. The patients whose SII had increased after one cycle of treatment showed a poorer PFS (HR 1.61; 95 %CI 1.10-2.37; P = 0.015) and OS (HR 1.76; 95 % CI 1.15-2.70; P = 0.009) than patients whose SII had decreased. The objective response rate (ORR) was higher in the SII-decreased patients (47.5% vs 32.5%, P = 0.11). Mann-Whitney test found a significant difference in therapeutic response between the SII-increased patients and the SII-decreased patients (P = 0.04).

Conclusion: SII can be associated with outcomes in patients with HBV-HCC treated with first-line lenvatinib plus PD-1 inhibitors.

Abstract Image

查看原文本刊更多论文

全身免疫炎症指数（SII）的变化可预测接受来伐替尼加PD-1抑制剂治疗的乙肝相关肝细胞癌患者的预后。

目的：本研究旨在评估接受一线来伐替尼联合程序性细胞死亡蛋白1（PD-1）抑制剂治疗的乙肝病毒相关肝细胞癌（HBV-HCC）患者炎症指标变化的预后意义：本研究回顾性纳入了117例接受来伐替尼联合PD-1抑制剂一线治疗的HBV-HCC患者。根据一个治疗周期后的基线指标和炎症指标变化，探讨了影响无进展生存期（PFS）和总生存期（OS）的独立因素：多变量分析显示，甲胎蛋白（AFP）水平⩾ 400 ng/mL [危险比（HR），1.69；95% 置信区间（CI），1.11-2.58；P = 0.01]为独立危险因素，血小板与中性粒细胞比值（PNR）⩽ 65.43（HR 0.50；95% CI 0.30-0.84；P 0.01）和 SII ⩽ 539.47（HR 0.54；95% CI 0.30-0.96；P = 0.03）为 PFS 的独立保护因素。此外，多变量分析表明，AFP ⩾ 400 ng/mL、HBV-HCC 患者伴有糖尿病（DM）以及 SII > 303.66 是 OS 的独立危险因素。治疗一个周期后，SII升高的患者的PFS（HR 1.61；95 %CI 1.10-2.37；P = 0.015）和OS（HR 1.76；95 %CI 1.15-2.70；P = 0.009）比SII降低的患者差。SII下降患者的客观反应率（ORR）较高（47.5% vs 32.5%，P = 0.11）。Mann-Whitney 检验发现，SII 增加的患者与 SII 减少的患者在治疗反应上存在显著差异（P = 0.04）：结论：SII与接受来伐替尼加PD-1抑制剂一线治疗的HBV-HCC患者的预后有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.